Aspen Aerogels (NYSE:ASPN – Get Free Report) had its price objective lowered by research analysts at B. Riley from $35.00 to $22.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the construction company’s stock. B. Riley’s price target would indicate a potential upside of 154.31% from the stock’s current price.
Several other research analysts have also weighed in on ASPN. Seaport Res Ptn lowered Aspen Aerogels from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 12th. Craig Hallum decreased their price target on Aspen Aerogels from $21.00 to $18.00 and set a “buy” rating for the company in a research note on Friday, February 14th. StockNews.com raised shares of Aspen Aerogels to a “sell” rating in a report on Wednesday. Barclays cut their target price on shares of Aspen Aerogels from $25.00 to $13.00 and set an “overweight” rating on the stock in a report on Wednesday. Finally, Canaccord Genuity Group cut their target price on shares of Aspen Aerogels from $20.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, February 14th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.44.
View Our Latest Research Report on Aspen Aerogels
Aspen Aerogels Stock Up 1.3 %
Aspen Aerogels (NYSE:ASPN – Get Free Report) last released its earnings results on Wednesday, February 12th. The construction company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.11. Aspen Aerogels had a return on equity of 7.49% and a net margin of 2.95%. Equities research analysts expect that Aspen Aerogels will post 0.46 earnings per share for the current year.
Institutional Investors Weigh In On Aspen Aerogels
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Abbot Financial Management Inc. grew its position in Aspen Aerogels by 3.9% in the fourth quarter. Abbot Financial Management Inc. now owns 30,255 shares of the construction company’s stock worth $359,000 after buying an additional 1,146 shares during the last quarter. Franklin Resources Inc. grew its position in Aspen Aerogels by 5.3% in the third quarter. Franklin Resources Inc. now owns 29,418 shares of the construction company’s stock worth $815,000 after buying an additional 1,483 shares during the last quarter. Invesco Ltd. grew its position in Aspen Aerogels by 3.5% in the fourth quarter. Invesco Ltd. now owns 50,871 shares of the construction company’s stock worth $604,000 after buying an additional 1,724 shares during the last quarter. Greenwood Capital Associates LLC grew its position in Aspen Aerogels by 5.0% in the fourth quarter. Greenwood Capital Associates LLC now owns 36,938 shares of the construction company’s stock worth $439,000 after buying an additional 1,749 shares during the last quarter. Finally, MetLife Investment Management LLC grew its position in Aspen Aerogels by 6.3% in the fourth quarter. MetLife Investment Management LLC now owns 35,782 shares of the construction company’s stock worth $425,000 after buying an additional 2,118 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.
About Aspen Aerogels
Aspen Aerogels, Inc designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier.
Recommended Stories
- Five stocks we like better than Aspen Aerogels
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Intel Surges on M&A Talks: Rally Beginning or Just a Headfake?
- Differences Between Momentum Investing and Long Term Investing
- Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here?
- P/E Ratio Calculation: How to Assess Stocks
- Up Nearly 1000%, Can AppLovin Keep Delivering for Investors?
Receive News & Ratings for Aspen Aerogels Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspen Aerogels and related companies with MarketBeat.com's FREE daily email newsletter.